关注
Andrew Spencer
Andrew Spencer
Professor of Haematology
在 monash.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ...
The lancet oncology 17 (8), e328-e346, 2016
25562016
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ...
Journal of clinical oncology 33 (26), 2863, 2015
21822015
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
M Dimopoulos, A Spencer, M Attal, HM Prince, JL Harousseau, ...
New England Journal of Medicine 357 (21), 2123-2132, 2007
19772007
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ...
New England Journal of Medicine 375 (8), 754-766, 2016
16812016
Elotuzumab therapy for relapsed or refractory multiple myeloma
S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ...
New England Journal of Medicine 373 (7), 621-631, 2015
15222015
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer …
DH Henry, L Costa, F Goldwasser, V Hirsh, V Hungria, J Prausova, ...
J Clin Oncol 29 (9), 1125-1132, 2011
15032011
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label …
MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ...
The Lancet Oncology 17 (1), 27-38, 2016
9992016
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy …
RZ Orlowski, A Nagler, P Sonneveld, J Bladé, R Hajek, A Spencer, ...
Journal of Clinical Oncology 25 (25), 3892-3901, 2007
7822007
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
MA Dimopoulos, C Chen, A Spencer, R Niesvizky, M Attal, EA Stadtmauer, ...
Leukemia 23 (11), 2147-2152, 2009
5362009
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
A Palumbo, S Bringhen, H Ludwig, MA Dimopoulos, J Bladé, MV Mateos, ...
Blood, The Journal of the American Society of Hematology 118 (17), 4519-4529, 2011
4662011
International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease
E Terpos, G Morgan, MA Dimopoulos, MT Drake, S Lentzsch, N Raje, ...
Journal of clinical oncology 31 (18), 2347, 2013
4452013
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation …
A Spencer, HM Prince, AW Roberts, IW Prosser, KF Bradstock, L Coyle, ...
J Clin Oncol 27 (11), 1788-1793, 2009
4372009
Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse
F van Rhee, F Lin, JO Cullis, A Spencer, NC Cross, A Chase, ...
4291994
Thalidomide for treatment of multiple myeloma: 10 years later
A Palumbo, T Facon, P Sonneveld, J Blade, M Offidani, F Gay, P Moreau, ...
Blood, The Journal of the American Society of Hematology 111 (8), 3968-3977, 2008
4052008
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a …
F Gay, S Oliva, MT Petrucci, C Conticello, L Catalano, P Corradini, ...
The lancet oncology 16 (16), 1617-1629, 2015
3642015
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and …
M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ...
The Lancet Haematology 7 (6), e456-e468, 2020
3362020
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
A Palumbo, S Bringhen, SK Kumar, G Lupparelli, S Usmani, A Waage, ...
The lancet oncology 15 (3), 333-342, 2014
3362014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem …
A Palumbo, SV Rajkumar, JF San Miguel, A Larocca, R Niesvizky, ...
Journal of clinical oncology 32 (6), 587, 2014
3112014
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, ...
Haematologica 103 (12), 2079, 2018
2972018
BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1
SJ Hogg, SJ Vervoort, S Deswal, CJ Ott, J Li, LA Cluse, PA Beavis, ...
Cell reports 18 (9), 2162-2174, 2017
2772017
系统目前无法执行此操作,请稍后再试。
文章 1–20